Vimta Labs to invest Rs. 50 crores to Biologics CDMO business foray
The foray into this new segment will help Vimta to enter into the growing CDMO business of biologics and peptides
The foray into this new segment will help Vimta to enter into the growing CDMO business of biologics and peptides
The positive opinions are based on applications submitted by Biosimilar Collaborations Ireland Limited
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
The company has reported total income of Rs. 628.4 crores during the period ended March 31, 2025
Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA modelsfeatured in two peer-reviewed articles
The 27 greenfield labs across the country ensure timely and accurate reporting
The implementation, spearheaded by Deloitte Consulting, brings together domain expertise and cutting-edge technology
The company delivered revenues of Rs. 5,554 crore, representing 10% growth in FY25
Access to NIPT, TB and Rare Disease diagnostics to benefit thousands of patients nationwide
Subscribe To Our Newsletter & Stay Updated